Living cells must be able to respond to physiological and environmental fluctuations that threaten cell function and viability. A cellular event prone to disruption by a wide variety of internal and external perturbations is protein folding. To ensure protein folding can proceed under a range of conditions, the cell has evolved transcriptional, translational, and posttranslational signaling pathways to maintain folding homeostasis during cell stress. This review will focus on oxidative protein folding in the endoplasmic reticulum (ER) and will discuss the features of the main facilitator of biosynthetic disulfide bond formation, Ero1. Ero1 plays an essential role in setting the redox potential in the ER and regulation of Ero1 activity is central to maintain redox homeostasis and proper ER folding activity.
Introduction
As the first organelle in the secretory pathway, the endoplasmic reticulum (ER) is dedicated to the folding and assembly of secretory proteins and is enriched for enzymes that assist several steps in the folding process [for reviews see [1, [2] [3] [4] ]. Molecular chaperones act as folding catalysts, for the initial transition from unfolded polypeptide to tertiary structure, and later in quality control, to ensure that only native folded proteins exit the ER into the secretory pathway. Enzymatic modification of newly synthesized polypeptides, including carbohydrate addition and disulfide bridge formation, also play an important role in protein folding and quality control. These modifications promote long-term protein stability for folded conformations and are an essential step in the folding process of many secretory proteins.
Pharmacological or physiological disruption of ER folding events leads to the buildup of unfolded polypeptides in the ER lumen and ER stress. When the folding demand of the ER surpasses the folding capacity of the ER, cells respond by inducing the unfolded protein response (UPR) [5, 6] . In this ERto-nucleus signaling pathway, sensors in the ER recognize unfolded proteins and transmit information across the ER membrane to activate downstream transcription factors, which in turn control an extensive gene-expression program. Genes induced by the UPR increase the ER folding capacity by expanding the ER lumen and augmenting the complement of folding chaperones and modifying enzymes. UPR induction also enhances the removal of irreparably misfolded proteins from the lumen by ER-associated degradation (ERAD). Prolonged UPR induction that does not reestablish homeostasis to the ER folding capacity leads to apoptosis.
An ER folding step that is acutely sensitive to perturbations of the lumenal ER environment is disulfide bond formation. Oxidative protein folding depends upon the maintenance of sufficiently oxidizing conditions within the ER lumen. A too reducing ER environment is unfavorable to disulfide bond formation [7] . Conversely, an overly oxidizing ER can lead to trapping of polypeptides in misoxidized misfolded states [8] . The membrane associated flavoprotein Ero1 is a significant source of oxidizing equivalents for the ER lumen and thus is responsible for setting the ER oxidation state [9, 10] . Pharmacological disruption of disulfide bond formation (by addition of exogenous reductant) leads to UPRmediated induction of ERO1 [9] [10] [11] . We have recently shown that both oxidative and reductive shifts in the ER environment are counteracted also by posttranslational regulation of Ero1 activity through two non-catalytic "regulatory" cysteine pairs [12] . We have proposed that the modulation of Ero1 activity (by changes in the redox state of its regulatory cysteine pairs) is part of a homeostatic feedback system in the ER that allows the cell to rapidly offset potentially detrimental fluctuations in the ER redox environment and maintain conditions conducive for oxidative protein folding [12] . Herein we will discuss Ero1 function in the cell and the future directions and questions relating to the regulation of Ero1 activity and ER homeostasis.
Ero1 catalyzes disulfide bond formation in the ER
Ero1 (ER oxidoreductin) is a glycosylated flavoenzyme tightly associated with the lumenal face of the ER membrane. ERO1 was characterized first genetically in two parallel screens in Saccharomyces cerevisiae [9, 10] . Loss-of-function Ero1 mutants in yeast fail to provide oxidizing equivalents to the ER for disulfide bond formation and consequently accumulate reduced misfolded proteins in the ER [9, 10] . Currently, Ero1 proteins have been characterized in several additional organisms including Homo sapiens [13, 14] , Caenorhabditis elegans [15] , Arabadopsis thaliana [16] , and Schizosaccharomyces pombe [17] . Not surprisingly, the most extensive studies on Ero1 have focused on S. cerevisiae and H. sapiens.
Ero1 and the thioredoxin-like protein protein disulfide isomerase (PDI) form the major pathway for protein disulfide bond formation in the eukaryotic ER. Ero1 influences protein oxidation by coupling the oxidizing power of molecular oxygen and its flavin cofactor to generate disulfide bonds [18] [19] [20] . These disulfides are transferred from Ero1 to the soluble disulfide-carrier PDI, which directly transfers its disulfides to folding secretory proteins [21] [22] [23] . Transfer of electrons from substrate proteins to PDI, and from PDI to Ero1, proceeds as a series of direct thiol-disulfide exchange reactions [20] [21] [22] [23] [24] [25] . In vitro reconstitution of the Ero1-PDI-substrate oxidation system with purified components solidified the capability and sufficiency of this pathway for protein disulfide generation [20] .
Despite an overall conservation of the Ero1-PDI pathway for disulfide bond formation among eukaryotes, a striking disparity between H. sapiens and S. cerevisiae systems is that human cells contain two Ero1 paralogs, Ero1-Lα and Ero1-Lβ (S. cerevisiae Ero1-like) [13, 14] while S. cerevisiae encodes a single Ero1 [9, 10] . Intriguingly, the presence of one or two ERO1 genes in an individual organism is not simply predicted by evolutionary criteria. In general, vertebrates have two ERO1 while invertebrates and fungi contain a single ERO1. However, exceptions do exist; two Ero1 proteins have been described in S. pombe (fungi) [17] and a BLAST search of Tribolium castaneum (flour beetle) reveals two Ero1-like proteins (accession numbers: XP_967561 and XP_972037). The significance of two Ero1 proteins encoded in a single genome is not clear and currently no major differences in redox activities or substrate interactions have been described between the characterized human paralogs. Both human proteins are functional homologs of S. cerevisiae Ero1 and can complement the phenotypic defects of the temperature-sensitive ero1-1 yeast strain [13, 14] . Human ERO1s show distinct transcriptional regulation and it is possible that more than one ERO1 allows cells to modulate the oxidizing potential of the ER under specific stress conditions [14, 26] . Similarly, plant ERO1s (AEROs) appear to possess different transcriptional regulatory elements, although transcriptional induction of AERO1 and AERO2 under stress conditions has not been analyzed [16] . Distinct tissue distribution for human Ero1-Lα and Ero1-Lβ also suggests the potential for tissue specific oxidation pathways [14] .
Ero1 uses an inter-cysteine relay to transfer disulfides to substrates
Ero1 uses two catalytic cysteine pairs (four cysteines) to oxidize PDI: the "active-site" and "shuttle" cysteines [27, 28] . The active-site cysteine pair is positioned adjacent to the redox active isoalloxazine moiety of the flavin cofactor, which is cradled by four antiparallel alpha-helices [29] (Fig. 1) . The shuttle cysteine pair, which comes in close proximity to the active-site cysteines, is located in a flexible polypeptide loop that rests on the surface of the protein and lacks significant secondary structure [29] (Fig. 1) . The catalytic cycle of Ero1 involves direct oxidation of PDI by the shuttle cysteine pair, and re-oxidation of the reduced shuttle cysteines through internal dithiol-disulfide exchange with the active site [24, 28] (Fig. 2) . The active-site cysteines of Ero1 are re-oxidized by transfer of their electrons to the flavin cofactor and molecular oxygen (producing hydrogen peroxide) [18] [19] [20] .
Movement of the Ero1 polypeptide loop containing the shuttle cysteines appears to be part of the Ero1 catalytic mechanism, helping to shuttle electrons from the redox-active Fig. 1 . Ero1 structure. Structure of yeast Ero1 residues 56-424 [29] . Cysteine side chains are represented as green and yellow spheres and the FAD cofactor is drawn as orange sticks. The polypeptide domain (residues 90-175) containing the shuttle cysteine pair is colored red. Note the two regulatory disulfides that contain one cysteine on the red region (Cys90 and Cys150) and one cysteine on the helical core (Cys295 and Cys349).
cysteines in PDI to the relatively obscured active-site cysteines in Ero1. Two crystal forms of Ero1 show two discrete conformations for the loop containing the shuttle cysteines, signifying the flexibility of this region of Ero1 in solution [29] . A catalytic mechanism involving electron shuttling between two cysteine pairs allows for specific oxidation of PDI and prevents the indiscriminate oxidation of ER proteins and small molecules by controlling access to the very oxidizing FAD-cysteine active-site couple in Ero1 [24] . The lack of secondary structure in the Ero1 polypeptide loop containing the shuttle cysteines may facilitate the association of Ero1 with PDI by mimicking PDI's natural substrate, an unfolded polypeptide.
Two non-catalytic cysteine pairs regulate Ero1 activity
Ero1 activity can be controlled through the redox state of two non-essential "regulatory" cysteine pairs in Ero1. These regulatory disulfides connect the extended polypeptide loop domain (containing the shuttle cysteines) to the surface of the helical core of Ero1 (Fig. 1) . The positioning of these non-catalytic cysteines, combined with the observed flexibility for the polypeptide region surrounding the shuttle cysteines [29] , has led us to propose that the regulatory cysteines pairs control the range of motion for the shuttle-cysteine-containing loop region to modulate Ero1 function [12] . Under oxidizing ER conditions, formation of the regulatory disulfides appears to tether the loop to the helical core, which restricts the movement of the shuttle cysteines and limits the ability of Ero1 to shuttle disulfides to PDI (Fig. 3) . Under reducing ER conditions, reduction of the regulatory disulfides likely enhances the range of motion for the polypeptide loop domain and increases Ero1 activity (Fig. 3) . We have suggested that the ability of the regulatory cysteines to sense the ER oxidation state and correspondingly alter Ero1 activity serves to offset fluctuations in the ER redox environment [12] .
Ero1 activity can be decoupled from its regulation in vivo by replacing one of the two regulatory cysteine pairs with alanine (Ero1-C150A-C295A) [12] . When this allele is transformed into yeast the second regulatory disulfide (Cys90-Cys349) becomes reduced, effectively creating a constitutively active, deregulated Ero1. Overexpression of this mutant allele inhibits yeast growth, which is likely a result of hyperoxidation of the ER and increased production of reactive oxygen species (hydrogen peroxide) in the ER [12, 15, 30] . The ability of a reducing agent (DTT) to alleviate the growth defect from Ero1-C150A-C295A overexpression confirmed that growth inhibition is a consequence of increased Ero1 activity and ER oxidation [12] .
Currently, redox regulation of Ero1 has been demonstrated only for S. cerevisiae Ero1. However, the presence of multiple cysteine residues, in addition to the catalytic cysteines, in all Ero1 homologs suggests the capacity for Ero1 regulation exists in different organisms. A positional equivalent for one (of the two) regulatory disulfides in yeast Ero1 (Cys90-Cys349) is present in almost all Ero1 homologs and likely forms a conserved regulatory disulfide bond; only one Ero1-like protein Fig. 2 . Ero1 catalytic mechanism. Cartoon-depiction of Ero1 shows the shuttle cysteines (red region), active-site cysteines (black), and FAD cofactor (orange). Thin arrows reflect electron flow. Fig. 3 . Posttranslational Ero1 regulation. The catalytic cysteines are shown as black ovals with white text and the extended non-helical polypeptide containing the shuttle cysteines is colored red. The regulatory cysteines are depicted as white "SS"-containing ovals when oxidized and black thiol "SH" groups when reduced. By tethering the non-helical loop domain to the protein core, formation of the regulatory disulfides may restrict mobility of the shuttle cysteines and decrease Ero1 activity under oxidizing ER conditions. When the regulatory disulfides are reduced, active Ero1 uses molecular oxygen to facilitate PDI and substrate protein oxidation.
sequence from the primordial eukaryote Encephalitozoon cuniculi lacks a positional equivalent for the yeast disulfide (accession number NP_584701). The second yeast Ero1 regulatory disulfide (Cys150-Cys295) is less conserved. However, human Ero1-Lα migrates as three distinct redox isoforms on non-reducing gels (R, Ox1, and Ox2), which is consistent with the presence of two regulated loop-to-core disulfides [21, 27] . There are three cysteines in the loop and two cysteines in the helical core region of Ero1-Lα that could form loop-tocore regulatory disulfides (Fig. 4) , although when the Ero1-Lα Cys208 and Cys241) and the loop cysteines appear to be too distant in space to form a disulfide bond. It is also possible that three redox forms for Ero1-Lα observed by SDS-PAGE reflect reduction of the Cys90-Cys349 equivalent (Cys85-Cys391) and/or reduction of an internal loop disulfide (e.g. between CysCys131 and Cys166, analogous to yeast Cys143-Cys166), which may extend the range of motion of the loop region. Mass spectrometry showed that the internal loop disulfide Cys143-Cys166 is reduced in activated yeast Ero1 [12] ; due to the short-range nature of this disulfide, its reduction does not significantly impact the mobility of yeast Ero1 on SDS-PAGE. Intriguingly, Ero1-Lα and Ero1-Lβ have the potential for unique regulatory disulfides based on an additional cysteine in the helical core domain of Ero1-Lβ that is absent in Ero1-Lα (Fig. 4, arrow C5 ).
Glutathione impacts Ero1 activity in the ER
Initial insight into the requirements for Ero1 regulatory disulfide reduction came with the observed impact of cellular glutathione levels on Ero1 activation in S. cerevisiae. Lowering cellular glutathione levels by treatment with an inhibitor of glutathione synthesis (buthionine sulfoxide) alleviates the growth defect from Ero1-C150A-C295A overexpression [12] . Examination of the redox state of Ero1-C150A-C295A in cells with lowered glutathione levels revealed that mutant Ero1 was in the oxidized inactive form [12] . These data suggest that glutathione normally plays a role in the reduction and activation of Ero1. Consistent with this interpretation, reduced glutathione has also been shown to influence transition between the Ox2 and Ox1 redox forms of human Ero1-Lα [31] . A role for glutathione depletion in alleviating oxidative stress from active Ero1 was initially unexpected based on glutathione's characterized role as an antagonist of the Ero1-PDI oxidation pathway [31, 32] . However, the inactivation of the hyperactive Ero1 mutant when glutathione is depleted prevents ER hyperoxidation, which appears to outweigh any potential negative impact of a diminished glutathione redox buffer [12] . As glutathione is a poor substrate and activator of purified Ero1 in vitro [12, 20, 24] , it seems unlikely that glutathione is a direct reductant of the regulatory disulfides. Instead, glutathione may affect the redox state of the regulatory disulfides indirectly by maintaining a direct reductant (perhaps PDI and/or related proteins) in a reduced form.
Activation of wild-type Ero1 proceeds as two sequential steps: (1) reduction of Cys150-Cys295 and (2) reduction of Cys90-Cys349 [12] . Cellular glutathione levels appear to differentially affect these two steps; step 2 appears to be dependent on cellular glutathione levels, whereas step 1 is independent of glutathione. A significant fraction of wild-type Ero1 is oxidized and inactive under standard growth conditions, indicating that normal levels of glutathione are insufficient to reduce Cys150-Cys295 [12] . In contrast, normal cellular glutathione levels cause almost complete reduction of Cys90-Cys349 in a mutant that can not form the Cys150-Cys295 disulfide bond (Ero1-C150A-C295A) [12] . Considering these data, we anticipate that Ero1 activation is initiated by a glutathione-independent redox factor that reduces Cys150-Cys295. In vitro this step can be facilitated by a PDI-like protein [12] , although the physiological reductant of Cys150-Cys295 in vivo remains to be identified. Reduction of Cys150-Cys295 likely triggers structural changes in the regulatory loop, exposing Cys90-Cys349 to Fig. 4 . Cysteines in yeast and human Ero1s. S. cerevisiae (Sc) Ero1 is depicted as a gray rectangle with lighter grey regions reflecting sequence absent in the crystal structure. Black denotes the four helices that form the catalytic core, red marks the extended loop polypeptide (residues 80-180), filled circles note cysteines (labeled with residue numbers), and solid lines show the cysteine connectivity from the crystal structure of yeast Ero1 [29] . Green circles reflect catalytic cysteines in S. cerevisiae and H. sapiens (Hs) Ero1, yellow circles note cysteines demonstrated to be regulatory in Sc Ero1 and predicted by conservation to be regulatory in Hs Ero1. Dotted lines indicated cysteines positionally conserved between Sc and Hs Ero1s. Arrows note three cysteines in the predicted loop region for Hs Ero1 (L1-3) and two cysteines in the core domain (C4-5) that have the potential to form regulatory loop-to-core disulfide bonds.
reduction by glutathione or a glutathione-dependent redoxactive enzyme. Use of multiple molecules to modulate the redox state of the two regulatory disulfides in Ero1 may ensure that Ero1 activation only occurs during defined ER redox conditions. Increased Ero1 activity in the ER enhances glutathione oxidation (GSSG formation) [12, 32] and also impacts glutathione synthesis [31] . It has been suggested that GSSG formation in the ER reflects glutathione-mediated reduction of (misoxidized) substrate proteins and/or PDI [20, [31] [32] [33] [34] . Considering the relationship between glutathione and Ero1 in the ER, it may seem incongruous that Ero1 activity would both generate ROS and deplete a scavenger of ROS, reduced glutathione. Increased glutathione synthesis under oxidative stress may allow for ROS inactivation, even in the presence of an increased rate of glutathione oxidation. Consistent with a role for glutathione in ROS elimination, addition of exogenous glutathione or cysteine (a glutathione precursor) prevented ROS accumulation under conditions that normally lead to enhanced ROS levels in the ER lumen [15, 30] .
Ero1 regulation influences ER physiology
It is interesting to consider the potential implications for the regulation of Ero1 activity on additional redox-active species in the ER. The redox reaction catalyzed by a given oxidoreductase (oxidation, reduction, or isomerization) is determined by the redox state of its active-site cysteine pairs. An inability to regulate Ero1 activity may lead to unwanted oxidation of reductases or isomerases in the ER, which is likely to negatively impact ER physiology by preventing reduction/isomerization of misoxidized substrates. Reduction of protein disulfides has been shown to precede dislocation and degradation of misfolded proteins targeted for ER-associated degradation [35, 36] and ER hyperoxidation may also prevent the reductase activity necessary to clear misfolded ERAD substrates. Conversely, modulation of the redox state and activity of PDI through regulation of Ero1 activity may be beneficial to cells and facilitate the response and recovery from fluctuations in the ER redox environment. Under steady-state conditions, approximately 70% of yeast PDI active sites are oxidized [37] . Accumulation of more PDI in the reduced form when Ero1 function is compromised could augment the amount of PDI available as a reductase or isomerase and promote the reshuffling of nonnative disulfide bonds accumulated during oxidative stress. The enhanced chaperone activity of reduced PDI may also help alleviate the load of misoxidized proteins by stimulating their unfolding, dislocation, and degradation [38] .
The potential for regulation of PDI redox activity by feedback regulation of Ero1 has interesting evolutionary implications on the divergence of oxidative protein folding pathways from bacteria to eukaryotes. In bacteria, two separate pathways are used to maintain oxidized and reduced pools of enzymes in the periplasmic space for protein oxidation and isomerization [reviewed in [39, 40] ]. These competing oxidation (DsbB-DsbA) and reduction/isomerization (DsbD-DsbC) pathways are kept distinct due to steric incompatibility of the soluble PDI-like component of one pathway (DsbA or DsbC) and the membrane-embedded component of the opposing pathway (DsbB or DsbD) [41] [42] [43] . Regulation of Ero1 to control the activity of PDI may provide a means for a single oxidoreductase to catalyze both protein oxidation and reduction. A single system centered upon PDI would explain why a dedicated protein-based reduction pathway in the ER analogous to the DsbD-DsbC system in the bacterial periplasm has not been identified in eukaryotes.
Ero1's role in oxidative protein folding and ER stress
Ero1 activity generates one molecule of hydrogen peroxide for each biosynthetic disulfide bond formed [18] . Correspondingly, experiments in yeast and worms have implicated Ero1 activity in the accumulation of ROS in the ER of whole cells [15, 30] . An intriguing rough calculation estimates that Ero1 activity may be a significant cause of cellular ROS, especially in cells with heavy secretory loads, accounting for up to 25% of the ROS produced during protein synthesis [44] . Although Ero1 appears to be a major source of ER peroxides, the absence of chronic oxidative stress suggests that the cell can cope with peroxides formed during routine protein folding. When ROS production exceeds the capacity of these antioxidant defense systems, it is anticipated that cellular redox homeostasis will be altered and oxidative stress ensue.
Controlling the production of amino acids for protein and glutathione biosynthesis appears to be one means to protect cells against oxidative stress and avert cellular damage from ROS accumulation. In multicellular eukaryotes, accumulation of misfolded proteins in the ER leads the stress-activated kinase PERK to phosphorylate the alpha subunit of the translation initiation factor 2 (eIF2α), which inhibits general protein synthesis and enhances the translation and expression of the transcription factor ATF4 [reviewed in [5] ]. Treating mouse or worm cells lacking PERK with agents that perturb protein folding in the ER (e.g. tunicamycin) leads these cells to accumulate ROS [15] . ROS buildup in the ER under these conditions depends on oxidative protein folding and Ero1 activity [15] . PERK is thought to defend against Ero1-mediated oxidative stress through ATF4-mediated activation of antioxidant responses and cysteine sufficiency and accordingly ROS levels abate with the exogenous addition of cysteine (oxidized cysteine, which is rapidly converted to reduced cysteine after cellular import) [15] . PERK-mediated translation attenuation may protect cells also against ROS accumulation by decreasing the quantity of proteins undergoing oxidative protein folding. In addition, it is possible that inactivation of the PERK signaling cascade interferes with feedback regulation of Ero1 activity, leading to increased Ero1 activity and ROS production. However, increased levels of ROS have not been detected in yeast overexpressing deregulated Ero1 (Ero1-C150A-C295A) [12] , suggesting that deregulation of Ero1 activity alone may not be sufficient to explain ROS accumulation in tunicamycintreated PERK mutants.
Fungi do not contain PERK. However, yeast does contain an ATF4-like transcription factor Gcn4 that is activated by the stress of amino acid starvation [reviewed by [45] ]. Intriguingly, Gcn4 is responsible for activating approximately one-third of the genes induced by treatment with the alkylating agent methyl methanesulfonate (MMS), suggesting a potential role for Gcn4 in the response to oxidative stress [46] . Gcn4 has also been shown to collaborate with Hac1 to stimulate transcriptional induction of UPR genes during ER stress [47] .
ER-associated degradation (ERAD) also appears to prevent ROS buildup by clearing misfolded proteins from the ER and thereby preventing persistent cycles of futile oxidation by Ero1. In yeast, increased ROS levels in the ER have been observed by stressing the ER folding machinery with dual hits in the oxidative folding and degradation systems; overexpression of a protein prone to misfolding (CPY ⁎ ) in a strain unable to clear the nonnative protein from the ER lumen due to a mutation in the ERAD system (erv29Δ) leads to prolonged activation of the UPR and ROS production [30] . Here, it has been suggested that accumulation of toxic levels of ROS is caused by the futile cycling of the Ero1-PDI oxidation cycle along with the depletion of the ROS scavenger glutathione [30] . Intriguingly, preventing induction of the UPR (ire1Δ or hac1Δ) in the CPY ⁎ erv29Δ strain alleviates ROS accumulation [30] , suggesting that UPR activation may exacerbate rather than alleviate oxidative folding stress.
Ero1 function in oxidative stress and disease
Cells expected to be particularly susceptible to changes in Ero1 activity include specialized secretory cells that express large quantities of disulfide-bonded proteins. Correspondingly, Ero1 could potentially have profound effects on the development of diabetes by impacting the folding and secretion of insulin by pancreatic β-cells. Changes in the redox status of the ER and Ero1 have been observed in (streptozotocininduced) diabetic rats [48] . Intriguingly while an overall reductive shift was observed in diabetic rat microsomes, Ero1 was observed in a more oxidized state [48] , which could reflect oxidation of the regulatory disulfides and Ero1 inactivation. Conversely, increased Ero1 activity and/or inefficient inactivation may also lead to aberrant β−cell physiology. In the Akita mouse, a spontaneous cysteine-to-tyrosine (C96Y) mutation in the insulin-2 gene (Ins-2) precludes formation of one of two disulfide bonds and causes early-onset diabetes and decreased β−cell mass [49] . Retention of mutant malfolded insulin-2 protein in the ER perturbs β−cell function, which could be due to increased Ero1 activity and ROS production caused by repeated cycles of futile disulfide formation [30, 50] . Ero1 has been suggested also to have a role in both oxidative folding and release of thiol-mediated ER retention of the insulinsensitizing hormone adiponectin [51, 52] . Conceivably, decreased levels of active Ero1 could inhibit adiponectin secretion and contribute to the lower plasma levels of adiponectin in humans and animals with obesity and insulinresistant diabetes.
The essential role for Ero1 in oxidative folding and cell viability makes Ero1 a possible target for pharmacological intervention in disease. ERO1 is one of eight genes associated with poor prognosis for lung adenocarcinomas [53] . Ero1 activity in hypoxic tumor cells improves protein secretion of the proangiogenic factor VEGF and targeted inhibition of Ero1 activity may inhibit tumor growth by preventing VEGF-driven angiogenesis. [54] . Neonatal exposure to sublethal hypoxic conditions confers neuroprotection to later hypoxic insult, which is thought to be a result of induction of vasoregulatory mediators (including ERO1) that improve vascular ability to maintain blood flow to the brain during later hypoxic challenges [55] . Ability to recreate this neuroprotective pathway could prevent ischemic neuronal cell death, which is a principal neuropathological feature of stroke.
Conclusions
Since the first identification of Ero1 approximately ten years ago, significant progress has been made toward understanding the mechanisms used by Ero1 to facilitate disulfide bond formation. Recognition of Ero1 as a central player in the maintenance of cellular redox homeostasis provides a focal point for future studies relating to how redox regulation in the ER is coupled with cellular physiology. Elucidating the role for Ero1 activity and regulation in both basic cell growth and pathological conditions is likely to have significant impact for understanding the role of Ero1 and oxidative stress in health and disease.
